
Top Videos From 2026 Dermatology Meetings: 12 Expert Interviews to Watch
Watch the top HCPLive video interviews from 2026 dermatology meetings, including AAD, RAD, EADV, Maui Derm, SDPA, and Fall Clinical.
From Maui Derm Hawaii in January to the Fall Clinical Dermatology Conference in October, HCPLive’s on-site video coverage of 2026 dermatology meetings spanned oral psoriasis therapies, new mechanisms in alopecia areata and cutaneous lupus, and a growing field of JAK inhibitors in vitiligo. Across 7 meetings, the interviews below were the top-performing videos from each.
Here are 12 dermatology meeting videos clinicians should watch from 2026.
Maui Derm Hawaii 2026
1.
At the 2026 Maui Derm Hawaii meeting, 7 dermatology and rheumatology leaders previewed the therapies and tools expected to shape practice this year. Linda Stein Gold, MD, called 2026 a possible “year of the oral psoriasis therapy,” citing the oral IL-23 inhibitor icotrokinra and next-generation TYK2 inhibitors. Neal Bhatia, MD, highlighted denifanstat, a fatty acid synthase inhibitor in development for moderate-to-severe acne, while Lawrence Eichenfield, MD, raised open questions on long-term immune modulation in atopic dermatitis.
AAD 2026 Annual Meeting
2.
In a formal debate at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Andrew Blauvelt, MD, MBA, argued IL-23 inhibitors may lower the risk of psoriatic arthritis (PsA) in patients with psoriasis who do not yet have joint disease. Up to 30% of patients with psoriasis develop PsA, typically 5 to 7 years after skin onset, and observational data suggest lower progression rates with IL-23 pathway agents. The prospective phase 4 PAMPA trial of guselkumab is testing the hypothesis, with data not yet mature.
David Rosmarin, MD, of Indiana University School of Medicine presented late-breaking phase 2b REZOLVE-AA data on rezpegaldesleukin, a first-in-class regulatory T-cell agonist, in severe-to-very-severe alopecia areata. Both doses produced about a 30% mean reduction in SALT score at week 36 versus 6% with placebo, with no efficacy plateau by week 36. Injection site reactions were the most common adverse event, with no increase in serious infections, major adverse cardiovascular events, thrombosis, or malignancy.
SDPA Summer Dermatology Conference 2026
4.
At the 2026 SDPA Summer Dermatology Conference, Douglas DiRuggiero, PA-C, of Skin Cancer & Cosmetic Dermatology reviewed lung disease as an emerging comorbidity in psoriasis. He cited a November 2025 Respiratory Medicine study of roughly 250 patients with moderate-to-severe psoriasis and chest CT imaging, in which pulmonary abnormalities such as ground-glass opacities were more common, a pattern now termed psoriasis-associated lung disease (PsO-LD). The panel also shared low-cost pearls for molluscum contagiosum and warts, including a heating pad approach described by Ted Rosen, MD.
5.
This video feature brings together 3 dermatologists on how prior authorization, step therapy, and formulary restrictions from insurers and pharmacy benefit managers slow patient access to biologics and targeted therapies. Harrison Nguyen, MD, MBA, MPH, described the staff time and paperwork required to secure approvals, while Shannon Trotter, DO, noted both practices and payers now use artificial intelligence (AI) in the process. The interviews also address potential reforms to the authorization system.
Revolutionizing Atopic Dermatitis (RAD) 2026
6.
At the 2026 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Christopher Bunick, MD, PhD, of Yale School of Medicine moderated a case-based session on FDA-approved atopic dermatitis therapies. The discussion compared IL-4 receptor alpha blockers, IL-13-targeted agents, IL-31 receptor alpha blockers, and oral JAK inhibitors across real-world scenarios. Bunick emphasized disease heterogeneity, noting no single agent works for every patient and many patients require switches or combination approaches.
David Rosmarin, MD, reviewed the atopic dermatitis pipeline at RAD 2026, including STAT6 degraders and inhibitors, an ITK inhibitor, a longer-acting IL-13 agent, and bispecific approaches pairing IL-13 with TSLP or IL-18. He identified chronic hand eczema as an area of persistent unmet need given its mixed atopic, allergic, and irritant causes. On trial interpretation, Rosmarin favored consistency across EASI-75, EASI-90, pruritus NRS, and IGA 0/1 over any single endpoint.
Maui Derm NP+PA Summer 2026
8.
HCPLive Five distills 5 practice takeaways for nurse practitioners and physician assistants from Maui Derm NP+PA Summer 2026, held June 24 to 27 in Colorado Springs. Topics include IL-13 inhibitor response as a guide for patch testing in eczematous dermatitis, rosacea management from pediatric erythema to phymatous disease, autoimmune blistering disease, hair loss, and the oral JAK inhibitor pipeline in vitiligo.
9.
George Martin, MD, of the Dermatology and Laser Center of Maui reviewed depigmentation and hyperpigmentation disorders at Maui Derm NP+PA Summer 2026. He said topical ruxolitinib, the only FDA-approved topical therapy for vitiligo, continues to increase repigmentation 2 to 3 years into treatment, while patients with more than about 50% body surface area involvement need systemic options. Martin pointed to oral JAK inhibitors including povorcitinib and ritlecitinib as candidates to expand systemic treatment.
EADV Congress 2026
10.
At the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Christopher G. Bunick, MD, PhD, discussed week-52 results from the phase 4 UnlIMMited trial (NCT05969223) of risankizumab (Skyrizi) in genital and scalp psoriasis. Among patients continuing risankizumab, 81.5% had sPGA-G 0/1 for genital psoriasis and 72.5% reached scalp IGA 0/1 at week 52, with no new safety signals in data not yet peer-reviewed. Bunick also highlighted sexual health as an underdiscussed burden for patients with genital psoriasis.
11.
Victoria P. Werth, MD, of the University of Pennsylvania and François Chasset, MD, PhD, of Sorbonne Université discussed 52-week data from the phase 2 AMETHYST Part A trial (NCT05531565) of litifilimab, a BDCA2-targeting monoclonal antibody, in cutaneous lupus erythematosus (CLE). Among patients starting litifilimab at baseline, CLASI-70 response rose from 21.7% at week 24 to 28.8% at week 52, and placebo switchers began responding within about 4 weeks. Litifilimab received FDA Breakthrough Therapy designation for CLE in January 2026, and the phase 3 portion of AMETHYST is ongoing.
Fall Clinical Dermatology Conference 2026
12.
At the 2026 Fall Clinical Dermatology Conference in Las Vegas, Iltefat Hamzavi, MD, of Henry Ford Health outlined distinct roles for topical and oral JAK inhibitors in vitiligo. He positioned ruxolitinib cream for localized disease under 10% body surface area without signs of instability, and oral agents such as upadacitinib, ritlecitinib, and povorcitinib for rapidly progressive disease. Hamzavi advised caution with oral agents in patients with active cardiovascular risk, high body mass index, or a smoking history.
Related to this article








